The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the agreement, eligible patients will pay around $245 to $350 per month, the administration said.